# Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

> **NCT00326105** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 450 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Quetiapine fumarate

## Key facts

- **NCT ID:** NCT00326105
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326105, "Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00326105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*